Navicixizumab (OMP-305B83) is a bispecific antibody designed to inhibit both vascular endothelial growth factor (VEGF) and Delta-like ligand 4 (DLL4). This dual inhibition mechanism makes it a potent candidate for use in oncology research, particularly in studies involving ovarian, primary peritoneal, or fallopian tube cancers. Navicixizumab has shown potential for use in combination with Paclitaxel, enhancing its applicability in therapeutic research protocols aimed at targeting cancer angiogenesis and tumor growth.
Navicixizumab (OMP-305B83) is a bispecific antibody designed to inhibit both vascular endothelial growth factor (VEGF) and Delta-like ligand 4 (DLL4). This dual inhibition mechanism makes it a potent candidate for use in oncology research, particularly in studies involving ovarian, primary peritoneal, or fallopian tube cancers. Navicixizumab has shown potential for use in combination with Paclitaxel, enhancing its applicability in therapeutic research protocols aimed at targeting cancer angiogenesis and tumor growth.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
